Neuralstem (CUR) Sees Strong Trading Volume

Neuralstem, Inc. (NASDAQ:CUR) saw unusually-strong trading volume on Thursday . Approximately 2,551,417 shares were traded during mid-day trading, an increase of 321% from the previous session’s volume of 606,565 shares.The stock last traded at $2.08 and had previously closed at $2.08.

Separately, S&P Equity Research decreased their target price on Neuralstem from $2.26 to $1.91 in a research report on Thursday.

The company has a market capitalization of $31.50, a PE ratio of -1.25 and a beta of 1.60.

A hedge fund recently raised its stake in Neuralstem stock. National Asset Management Inc. increased its stake in Neuralstem, Inc. (NASDAQ:CUR) by 9.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,985 shares of the company’s stock after purchasing an additional 1,937 shares during the quarter. National Asset Management Inc. owned about 0.19% of Neuralstem worth $134,000 at the end of the most recent quarter. 7.05% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit